Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance.

By J. McCubrey, Linda S. Steelman, W. Chappell, Stephen L. Abrams, E. T. Wong, F. Chang, B. Lehmann, D. Terrian, M. Milella, A. Tafuri and 6 more. Biochimica et Biophysica Acta, 2007

2,329 citations recorded by the source corpus.

Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis. Some components of these pathways are mutated or aberrantly expressed in human cancer (e.g., Ras, B-Raf). Mutations also occur at genes encoding upstream receptors (e.g., EGFR and Flt-3) and chimeric chromosomal translocations (e.g., BCR-ABL) which transmit their signals through these cascades. Even in the absence of obvious genetic mutations, this pathway has been reported to be activated in over 50% of acute myelogenous leukemia and acute lymphocytic leukemia and is also frequently activated in other cancer types (e.g., breast and prostate cancers). Importantly, this increased expression is associated with a poor prognosis. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. For example, in some cells, PTEN mutation may contribute to suppression of the Raf/MEK/ERK cascade due to the ability of activated Akt to phosphorylate and inactivate different Rafs. Although both of these pathways are commonly thought to have anti-apoptotic and drug resistance effects on cells, they display different cell lineage specific effects. For example, Raf/MEK/ERK is usually associated with proliferation and drug resistance of hematopoietic cells, while activation of the Raf/MEK/ERK cascade is suppressed in some prostate cancer cell lines which have mutations at PTEN and express high levels of activated Akt. Furthermore the Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways also interact with the p53 pathway. Some of these interactions can result in controlling the activity and subcellular localization of Bim, Bak, Bax, Puma and Noxa. Raf/MEK/ERK may promote cell cycle arrest in prostate cells and this may be regulated by p53 as restoration of wild-type p53 in p53 deficient prostate cancer cells results in their enhanced sensitivity to chemotherapeutic drugs and increased expression of Raf/MEK/ERK pathway. Thus in advanced prostate cancer, it may be advantageous to induce Raf/MEK/ERK expression to promote cell cycle arrest, while in hematopoietic cancers it may be beneficial to inhibit Raf/MEK/ERK induced proliferation and drug resistance. Thus the Raf/MEK/ERK pathway has different effects on growth, prevention of apoptosis, cell cycle arrest and induction of drug resistance in cells of various lineages which may be due to the presence of functional p53 and PTEN and the expression of lineage specific factors.

Subfields: Molecular Biology

View Paper: https://www.semanticscholar.org/paper/e2fb03f177f3ff993e05d98f76ee16d8983b7de6

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation (2015, background): “As previously reported, EGFR remarkably increased the activity of ERK1/2 and AKT, which are involved in the proliferation, antiapoptosis, and invasion of tumor cells.(26,27) The upregulation of PD-L1 mediated by EGFR activation was associated with the activation of ERK1/2/cJun and AKT/S6 pathways.”
Drug repositioning for non-small cell lung cancer by using machine learning algorithms and topological graph theory (2016, background): “Raf/MEK/ERK is typically associated with the proliferation and drug resistance of hematopoietic cells, while the activation of the Raf/MEK/ ERK cascade is suppressed in some prostate cancer cell lines that have mutations at PTEN and express high levels of activated [44].”
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging (2011, background): “Moreover, chemotherapeutic drugs such as doxorubicin can induce the p53 activity that in turn can activate the expression of the discoidin domain receptor (DDR) which can induce Ras and the downstream Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt/mTOR pathways [196-198].”
Targeting the Mitogen-Activated Protein Kinase RAS-RAF Signaling Pathway in Cancer Therapy (2012, background): “Accordingly, Ras communicates external cellular signals to the nucleus, and its altered activation leads to inappropriate cellular activities including enhanced cell growth, differentiation, survival and ultimately to cancer [1,8,9].”
Role of ROS and Nutritional Antioxidants in Human Diseases (2018, background): “ROS also upregulate antiapoptotic genes and downregulate proapoptotic proteins via PI3K/AKT and ERK/MEK pathways (McCubrey et al., 2007).”
Exosome Uptake Depends on ERK1/2-Heat Shock Protein 27 Signaling and Lipid Raft-mediated Endocytosis Negatively Regulated by Caveolin-1 (2013, background): “Thus, future studies should explore the possibility of differential transfer of vesicles in the context of CAV1 and ERK1/2 expression, as these proteins are frequently deregulated at various stages of tumor development (38, 39).”
Reactive oxygen species in cancer (2010, background): “ovarian cancer, breast cancer, melanoma and leukemia) that the activation of Erk1/2 through ROS increases cell survival, anchorage-independent growth and motility [60, 65, 66].”